moxifloxacin has been researched along with cephalosporin c in 27 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (cephalosporin c) | Trials (cephalosporin c) | Recent Studies (post-2010) (cephalosporin c) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 20,476 | 2,093 | 4,152 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Capper, T; Klugman, KP | 1 |
| Frimodt-Møller, N; Knudsen, JD; Ostergaard, C; Sørensen, TK | 1 |
| Eiffert, H; Mäder, M; Nau, R; Schmidt, H; Stuertz, K; Trostdorf, F | 1 |
| Burke, T; Church, D; Haverstock, D; Heyd, A; Huck, W; Mariano, H; Orchard, D; Villanueva, C | 1 |
| Bagger-Sjöbäck, D; Gehanno, P; Hampel, B; Ibanez, JM; Nikolaidis, P; Siegert, R; Sommerauer, B | 1 |
| Ghaffar, F; Hardy, RD; Jafri, HS; McCoig, CC; McCracken, GH; Michelow, IC; Olsen, K; Patel, C; Rodriguez-Cerrato, V | 1 |
| Blandino, G; Caccamo, F; Milazzo, I; Musumeci, R; Nicoletti, G; Speciale, A | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Alteraz, H; Blau, H; Fabian, I; Horev-Azaria, L; Kariv, N; Kletter, Y; Shalit, I; Shechtman, I | 1 |
| Choi, JH; Choi, SM; Kim, SH; Lee, DG; Shin, WS; Song, MJ; Yoo, JH | 1 |
| Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
| Becker, K; Friedrich, AW; Peters, G; von Eiff, C | 1 |
| Farny, K; Michault, A; Picot, S; Simac, C | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Ednie, L; Lin, G; Shapiro, S; Smith, K | 1 |
| Beksac, MS; Katlan, D; Kir, S; Nemutlu, E; Ozyuncu, O | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Llorens, L; Rank, D; Rekeda, L; Riccobene, TA | 1 |
| Boucher, BA; Croce, MA; Fabian, TC; Monteen, MR; Ponnapula, S; Swanson, JM; Wood, GC | 1 |
| Eguchi, H; Hotta, F; Kusujima, K; Kuwahara, T; Mitamura, Y; Naito, T | 1 |
| Braga-Mele, R; Chang, DF; Henderson, BA; Mamalis, N; Talley-Rostov, A; Vasavada, A | 1 |
| Beydemir, Ş; Söyüt, H; Türkeş, C | 1 |
| Bai, P; Ding, Y; Luo, Y; Xiao, XM; Zhou, LY | 1 |
| Chen, L; Chen, X; Jia, X; Li, N; Liu, W; Sun, H; Tong, H; Xiang, R; Xu, Y; Zhang, F; Zhang, J; Zhao, H | 1 |
| Cheng, A; Chuang, YC; Sheng, WH; Wang, JT; Yang, JJ | 1 |
| Ahmed Khan, T; Azher, I; Sheikh, AK; Sheikh, M | 1 |
| Den Nagata, T; Katsube, T; Machida, M; Mason, JW; Migoya, E; Narukawa, Y; Sanabria, C; Stanworth, SH | 1 |
| Chobey, A; Kryvtsova, M; Kulynych, M; Mochalov, I | 1 |
1 review(s) available for moxifloxacin and cephalosporin c
| Article | Year |
|---|---|
Intracameral antibiotics: Safety, efficacy, and preparation.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cephalosporins; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pharmaceutical Preparations; Treatment Outcome; Vancomycin | 2014 |
4 trial(s) available for moxifloxacin and cephalosporin c
| Article | Year |
|---|---|
Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Cefuroxime; Cephalosporins; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Maxillary Sinusitis; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines | 1999 |
A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group.
Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Cefuroxime; Cephalosporins; Double-Blind Method; Drug Evaluation; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Sinusitis | 2000 |
Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval.
Topics: Adolescent; Adult; Aza Compounds; Ceftaroline; Cephalosporins; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Young Adult | 2013 |
Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects.
Topics: Adult; Anti-Bacterial Agents; Cefiderocol; Cephalosporins; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Healthy Volunteers; Heart; Heart Rate; Humans; Male; Moxifloxacin; Siderophores; Young Adult | 2019 |
22 other study(ies) available for moxifloxacin and cephalosporin c
| Article | Year |
|---|---|
Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Cephalosporins; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Penicillins; Quinolines; Quinolones; Streptococcus pneumoniae | 1997 |
Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Cephalosporins; Drug Evaluation; Fluoroquinolones; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Protein Binding; Quinolines; Quinolones; Rabbits; Streptococcus pneumoniae; Time Factors; Vancomycin | 1998 |
Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Cephalosporins; Disease Models, Animal; Fluoroquinolones; Immunoenzyme Techniques; Lipopolysaccharides; Meningitis, Pneumococcal; Moxifloxacin; Naphthyridines; Polysaccharides, Bacterial; Quinolines; Rabbits; Reference Values; Rifabutin; Teichoic Acids; Virginiamycin | 1999 |
Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Ceftriaxone; Cephalosporins; Escherichia coli; Fluoroquinolones; Male; Meningitis, Escherichia coli; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Thienamycins | 2001 |
Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Ceftriaxone; Cephalosporins; Ciprofloxacin; Clindamycin; Clostridium; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Imipenem; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma; Quinolines; Streptococcus; Teicoplanin; Thienamycins; Vancomycin | 2002 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Body Weight; Bronchopneumonia; Candidiasis; Ceftazidime; Cephalosporins; Cyclophosphamide; Cytokines; Fluoroquinolones; Lung; Male; Mice; Mice, Inbred BALB C; Moxifloxacin; Neutropenia; Protein Synthesis Inhibitors; Quinolines; Survival | 2002 |
Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells.
Topics: Adjuvants, Immunologic; Anti-Infective Agents; Aza Compounds; Blotting, Western; Ceftriaxone; Cell Survival; Cephalosporins; Cytokines; Enzyme-Linked Immunosorbent Assay; Escherichia coli; Flow Cytometry; Fluoroquinolones; Humans; I-kappa B Proteins; In Vitro Techniques; Interleukin-6; Lipopolysaccharide Receptors; Monocytes; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae; Tumor Necrosis Factor-alpha | 2003 |
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Cephalosporins; Fluoroquinolones; Genetic Variation; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Phenotype; Quinolines; Staphylococcal Infections; Staphylococcus | 2005 |
[Antimicrobial resistance of Streptococcus pneumoniae strains isolated in the Reunion Island during 2004].
Topics: Aza Compounds; beta-Lactams; Cephalosporin Resistance; Cephalosporins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Ketolides; Moxifloxacin; Penicillin Resistance; Quinolines; Retrospective Studies; Reunion; Rifampin; Streptococcal Infections; Streptococcus pneumoniae; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Azithromycin; beta-Lactamases; Cefpodoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Ketolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Selection, Genetic | 2006 |
Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Cefepime; Cefoperazone; Cephalosporins; Female; Fetal Blood; Fluoroquinolones; Humans; Infant, Newborn; Injections, Intravenous; Levofloxacin; Maternal-Fetal Exchange; Moxifloxacin; Ofloxacin; Pregnancy; Pregnancy Complications, Infectious; Quinolines | 2010 |
In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Anaerobic; Ceftaroline; Ceftriaxone; Cephalosporins; Clindamycin; Fluoroquinolones; Imipenem; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines; Tigecycline | 2011 |
Treatment of Chryseobacterium indologenes ventilator-associated pneumonia in a critically ill trauma patient.
Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; Chryseobacterium; Critical Illness; Flavobacteriaceae Infections; Fluoroquinolones; Humans; Intensive Care Units; Male; Moxifloxacin; Pneumonia, Ventilator-Associated; Quinolines; Radiography; Wounds and Injuries | 2013 |
Achromobacter buckle infection diagnosed by a 16S rDNA clone library analysis: a case report.
Topics: Achromobacter; Anti-Bacterial Agents; Betamethasone; Cefdinir; Cephalosporins; Device Removal; DNA, Bacterial; DNA, Ribosomal; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Gram-Negative Bacterial Infections; Humans; Middle Aged; Moxifloxacin; Polymerase Chain Reaction; Prosthesis-Related Infections; Retinal Detachment; RNA, Ribosomal, 16S; Scleral Buckling | 2014 |
Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium.
Topics: Aryldialkylphosphatase; Cefepime; Cefotaxime; Ceftizoxime; Cephalosporins; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin | 2015 |
Susceptibility of Helicobacter pylori to antibiotics in Chinese patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Minocycline; Moxifloxacin; Peptic Ulcer; Risk Factors; Young Adult | 2015 |
[Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Topics: Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2016 |
Impact of broad-spectrum antimicrobial treatment on the ecology of intestinal flora.
Topics: Acinetobacter baumannii; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; Cephalosporins; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Feces; Female; Fluoroquinolones; Gastrointestinal Microbiome; Humans; Male; Microbial Viability; Middle Aged; Moxifloxacin; Pseudomonas aeruginosa; Taiwan | 2018 |
Burn aggravated infected wart in a patient with type 2 diabetes: a medical challenge.
Topics: Aged; Anti-Bacterial Agents; Burns; Cefepime; Cephalosporins; Diabetes Mellitus, Type 2; Fluoroquinolones; Foot; Foot Diseases; Humans; Male; Moxifloxacin; Pakistan; Saudi Arabia; Staphylococcal Infections; Staphylococcus aureus; Warts | 2018 |
Identification of Pathogenic Microflora and Its Sensitivity to Antibiotics in Cases of the Odontogenic Purulent Periostitis and Abscesses in the Oral Cavity.
Topics: Abscess; Anti-Bacterial Agents; Cephalosporins; Humans; Mouth; Moxifloxacin; Periostitis | 2023 |